Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (71-80 of 238) with videos related to

Pageof 24
Sort By:
The Journal of Biological Chemistry|June 27, 1997
Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growthJ A Engelman, C C Wykoff, S Yasuhara, et al.
Science Signaling|November 25, 2010
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutationRyan B Corcoran, Dora Dias-Santagata, Kristin Bergethon, et al.
Oncogene|June 29, 2010
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3A Chakrabarty, B N Rexer, S E Wang, et al.
The Journal of Biological Chemistry|December 10, 1999
Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesisJ A Engelman, A H Berg, R Y Lewis, et al.
The EMBO Journal|November 21, 1998
Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascadeF Galbiati, D Volonte, J A Engelman, et al.
Cancer Research|May 4, 2012
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsAlexa B Turke, Youngchul Song, Carlotta Costa, et al.
Cancer Research|January 27, 2011
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitorsJie Qi, Michele A McTigue, Andrew Rogers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkChristoph A Ritter, Marianela Perez-Torres, Cammie Rinehart, et al.
Cancer Research|April 20, 2013
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionRyohei Katayama, Aki Aoyama, Takao Yamori, et al.
FEBS Letters|September 17, 1998
Mutational analysis of caveolin-induced vesicle formation. Expression of caveolin-1 recruits caveolin-2 to caveolae membranesS Li, F Galbiati, D Volonte, et al.
Pageof 24

Showing results (71-80 of 238) with videos related to

Sort By:
Pageof 24
The Journal of Biological Chemistry|June 27, 1997
Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growthJ A Engelman, C C Wykoff, S Yasuhara, et al.
Science Signaling|November 25, 2010
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutationRyan B Corcoran, Dora Dias-Santagata, Kristin Bergethon, et al.
Oncogene|June 29, 2010
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3A Chakrabarty, B N Rexer, S E Wang, et al.
The Journal of Biological Chemistry|December 10, 1999
Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesisJ A Engelman, A H Berg, R Y Lewis, et al.
The EMBO Journal|November 21, 1998
Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascadeF Galbiati, D Volonte, J A Engelman, et al.
Cancer Research|May 4, 2012
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsAlexa B Turke, Youngchul Song, Carlotta Costa, et al.
Cancer Research|January 27, 2011
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitorsJie Qi, Michele A McTigue, Andrew Rogers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkChristoph A Ritter, Marianela Perez-Torres, Cammie Rinehart, et al.
Cancer Research|April 20, 2013
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionRyohei Katayama, Aki Aoyama, Takao Yamori, et al.
FEBS Letters|September 17, 1998
Mutational analysis of caveolin-induced vesicle formation. Expression of caveolin-1 recruits caveolin-2 to caveolae membranesS Li, F Galbiati, D Volonte, et al.
Pageof 24